Enovis (ENOV) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TransMedics Group (TMDX) has outperformed Enovis (ENOV) over the past year, losing 31.1% versus a loss of 43.6%. Over five years, TMDX leads with a +197.6% price change compared with -79.7% for ENOV. TransMedics Group is the larger company by market cap ($2.70 billion vs $1.02 billion), about 2.6 times the size.
On valuation, Enovis trades at a lower forward P/E (4.9x vs 34.5x for TransMedics Group). TransMedics Group converts more of its revenue into profit, with a net margin of 31.4% versus -52.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | TMDX |
|---|---|---|
| Share price | $17.69 | $77.87 |
| Market cap | $1.02B | $2.70B |
| 1-day change | +1.49% | -1.43% |
| YTD return | -33.60% | -35.99% |
| 1-year return | -43.61% | -31.08% |
| 5-year return | -79.70% | +197.55% |
| P/E ratio (TTM) | — | 20.17 |
| Forward P/E | 4.93 | 34.55 |
| EPS (TTM) | $-19.23 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.25B | $605.49M |
| Revenue growth (YoY) | +6.66% | +37.13% |
| Net income (latest FY) | $-1.18B | $190.29M |
| Gross margin | 59.84% | 59.92% |
| Operating margin | -50.01% | 17.93% |
| Net margin | -52.69% | 31.43% |
| 52-week high | $34.28 | $156.00 |
| 52-week low | $16.70 | $60.11 |
| Distance from 52-week high | -48.40% | -50.08% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +112.44% | +28.19% |
| Average volume | 1.46M | 824.76K |
| Shares outstanding | 57.67M | 34.68M |
| Employees | 7,802 | 898 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 2.6 times larger than Enovis by market value ($2.70B vs $1.02B).
- TMDX has outperformed ENOV by 12.5 percentage points over the past year.
- TransMedics Group is more profitable, keeping 31.4 cents of every revenue dollar as net income versus -52.7 cents for Enovis.
- TransMedics Group grew revenue faster in its latest fiscal year (+37.13% vs +6.66%).
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
ENOV vs TMDX FAQ
Which is bigger, Enovis or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.70B compared with $1.02B for Enovis (ENOV).
Which stock has performed better over the past year, ENOV or TMDX?
TMDX returned -31.08% over the past 12 months, compared with -43.61% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Are Enovis and TransMedics Group in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Enovis and Biotechnology: Electromedical & Electrotherapeutic Apparatus for TransMedics Group.